NCT04903197CompletedPhase 1
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 12 Jun 2024
- Start date
- 24 Jan 2022
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT04903197
- EU CT number
- 2024-511489-35-00
- EudraCT number
- 2020-005881-32
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Cologne AöR Coordinator of this site? Confirm its status | Cologne | Germany | Completed |
| Universitaetsmedizin Goettingen Coordinator of this site? Confirm its status | Goettingen | Germany | Completed |
| Universitaetsklinikum Leipzig Aor Coordinator of this site? Confirm its status | Leipzig | Germany | Completed |
| Hospital Universitario Ramón y Cajal Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Coordinator of this site? Confirm its status | Brescia | Italy | Completed |
| Humanitas Mirasole S.p.A. Coordinator of this site? Confirm its status | Rozzano | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.